F2 and deep vein thrombosis: Anti-prothrombin antibodies, not included in European Alliance of Associations for Rheumatology APS criteria, have been associated with a higher rate of thrombosis compared with negative anti-prothrombin patients (8.6 vs 3.6 per patient-year) [8].